Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2023-12-05 Regulatory Filings
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
BioInvent presents positive first clinical data on anti-FcyRIIB antibody BI-1607
Regulatory Filings Classification · 95% confidence The document is a press release dated December 5, 2023, announcing positive first clinical data for a drug candidate (BI-1607) presented at a symposium. It contains key results, management commentary, and information about future trials. Crucially, the final section explicitly states: "This information is information that BioInvent International is obliged to make public pursuant to the EU Market Abuse Regulation." This structure—a formal announcement of material, non-public information required for regulatory disclosure—points towards a general regulatory announcement. Since it is not a full financial report (10-K, IR), a specific earnings release (ER), or a management discussion (MDA), and it is not explicitly soliciting votes (DEF 14A/PSI), the most appropriate classification is the general regulatory filing category, RNS (Regulatory News Service/Announcement), which serves as a catch-all for mandatory disclosures that don't fit elsewhere. Although it contains elements of an Investor Presentation (IP) due to the data presentation, the context is a mandatory regulatory disclosure under EU MAR, making RNS the superior fit for this type of announcement.
2023-12-05 English
BioInvent presenterar positiva kliniska data för anti-FcyRIIB-antikroppen BI-1607
Earnings Release Classification · 95% confidence The document is a press release dated December 5, 2023, announcing positive clinical data for a drug candidate (BI-1607) presented at a symposium. It details preliminary results (safety profile, stable disease observations) and mentions that the full data will be presented in a poster. The text concludes with contact information and a statement about the information being subject to EU Market Abuse Regulation disclosure requirements. This format—a brief announcement of results or an event, often linking to an external presentation or filing—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is primarily focused on announcing clinical trial results and updates, it fits best under the 'Earnings Release' category, which often encompasses key operational and clinical updates for biotech firms, even if it's not strictly quarterly financial earnings. Given the content is a summary of clinical trial progress and not a comprehensive financial report (10-K or IR), ER is the most appropriate fit among the provided options for a significant operational update. FY 2023
2023-12-05 Swedish
BioInvent presents positive data at SITC from clinical Phase 1/2a trial of BI-1808 as single agent
Regulatory Filings Classification · 92% confidence The document is a press release dated November 3, 2023, announcing positive preliminary data from a clinical Phase 1/2a trial of a drug candidate (BI-1808) presented at the SITC Annual Meeting. It details efficacy signals, safety profiles, and future development plans. This format—a news announcement summarizing recent results or events—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a comprehensive financial report (10-K, IR) nor a transcript (CT), and it is announcing specific, time-sensitive operational/clinical results, it fits best as an Earnings Release (ER) if it were quarterly results, but since it is a specific clinical data presentation announcement, it is more accurately classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the slides themselves. Given the structure is a press release announcing data presentation, and it doesn't fit the specific definitions of ER (which usually covers financial performance), the most appropriate general category for significant, non-financial operational updates that must be disclosed is Regulatory Filings (RNS). However, because it is a detailed announcement of clinical trial data and future pipeline milestones, it strongly resembles the content often found in an Investor Presentation (IP) or a specialized update. Since the document is a press release announcing data presented elsewhere, and it is not a formal financial report, RNS is the safest fallback. Upon re-evaluation, the content is a direct announcement of clinical trial progress, which is a key piece of investor information. It is not a proxy statement (DEF 14A), a dividend notice (DIV), or a management discussion (MDA). Given the focus on clinical trial results and pipeline updates, it is a significant investor communication. Since there is no specific code for 'Clinical Trial Update', RNS is the general regulatory filing category. The document length is substantial (7296 chars), ruling out RPA based on the 'MENU VS MEAL' rule, as this is the substance, not just an announcement of the substance being attached.
2023-11-03 English
BioInvent presenterar positiva data på SITC från klinisk fas 1/2a-studie med BI-1808 som monoterapi
Regulatory Filings Classification · 91% confidence The document is a press release from BioInvent International AB dated November 3, 2023, announcing positive preliminary data from a Phase 1/2a clinical study of their drug candidate BI-1808, presented at the SITC conference. It details clinical results (partial response, stable disease, safety profile) and future milestones. This type of announcement, which releases key operational and clinical trial results outside of a formal quarterly/annual report, typically falls under an Earnings Release (ER) if it were focused on financial performance, or a general Regulatory Filing (RNS) if it's a broad operational update. However, since it is a detailed announcement of clinical trial results and scientific presentation data, it is most closely aligned with an Earnings Release (ER) which often includes operational highlights, or potentially an Investor Presentation (IP) if it were structured as slides, but as a press release detailing results, ER is the closest fit among the options for a periodic operational/results update, although it is not strictly financial earnings. Given the options, and that it is a formal announcement of results (even if clinical rather than purely financial earnings), ER is plausible, but RNS is the safest fallback for non-standard operational announcements. Reviewing the definitions, ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is a clinical result announcement. Since it is a formal announcement of significant operational/scientific progress, and not a proxy statement, management change, or formal financial report (10-K/IR), it fits best as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the presentation itself. Since it is the *press release* announcing the presentation, RNS (General regulatory announcements and fallback category) is the most appropriate classification for this type of corporate update that doesn't fit the specific financial or governance categories.
2023-11-03 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Q3 2023 for BioInvent. It contains comprehensive financial data (income statement, cash flow, balance sheet items), management commentary, and detailed updates on clinical trials and business operations. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year. 9M 2023
2023-10-26 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'UNLEASHING IMMUNITY TO FIGHT CANCER INTERIM REPORT Q3, 2023'. It contains detailed financial highlights, including net sales, profit/loss, cash flow, and liquid funds for the third quarter and the nine-month period ending September 30, 2023. It also provides a comprehensive review of clinical trial progress, pipeline updates, and management commentary. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and analysis, it is classified as an Interim/Quarterly Report. 9M 2023
2023-10-26 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.